SPERO BIOPHARMA
Committed to the prevention and treatment of Alzheimer's disease
BACKGROUND
Spero Biopharma Ltd. was founded by Prof. Marta Weinstock-Rosin, a world renowned researcher of Alzheimer disease. Prof. Weinstock-Rosin is the inventor of Exelon®, a blockbuster drug for the treatment of Alzheimer’s disease, and a professor emeritus at the Hebrew University’s School of Pharmacy-Institute for Drug Research in the Faculty of Medicine.
WHAT WE DO
Spero Biopharma’s lead compound is Ladostigil, an innovative treatment for Mild Cognitive Impairment (MCI)
Mechanism of action involves multiple neuro-protection functions Including reduction of microglial activation and inhibition of pro-inflammatory cytokines
A rich body of preclinical data
Ladostigil has completed a multinational phase-II trial in mild cognitive impairment with positive final results
World class scientific founder and advisory board
Comprehensive IP coverage
"Big results require big ambitions"